U.S. Non-alcoholic Steatohepatitis Biomarkers Market Size, Share, Trends & Forecast 2026-2034

Study Period

2021-2034

Market (2026)

USD 0.53 Billion

Market (2034)

USD 2.12 Billion

CAGR

18.90%

Major Markets Players

GENFIT, Prometheus Laboratories., Siemens Medical Solutions USA Inc., Quest Diagnostics, AstraZeneca and Others

*Note: Partial List Randomly Ordered

Key Takeaways

Market Overview

Non-alcoholic steatohepatitis (NASH) biomarkers are measurable indicators in blood or tissue that help assess liver inflammation, fibrosis, cell injury and oxidative stress. Clinicians, diagnostic laboratories and drug developers use them for risk stratification, patient selection, disease monitoring and clinical trial endpoints, offering a non-invasive complement to liver biopsy.

The U.S. Non-alcoholic Steatohepatitis Biomarkers Market is influenced by growing interest in non-invasive liver disease assessment and by recent treatment approvals. The FDA approved resmetirom in March 2024 and semaglutide in August 2025 for adults with MASH and moderate-to-advanced fibrosis, increasing the importance of identifying eligible patients through diagnostic technologies.

This U.S. Non-alcoholic Steatohepatitis Biomarkers Market Analysis shows demand centered on blood-based tests, multi-marker panels and research-driven biomarker validation. Pharmaceutical developers, laboratories and hospitals are the main participants. The market is projected to grow at a CAGR of 18.90% during 2026–2034.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Dynamics

Demand for non-invasive liver disease assessment, advances in blood-based diagnostics and pharmaceutical research on MASH shape adoption. Regulatory requirements, clinical validation needs and reimbursement coverage influence commercialization, test pricing and competition among diagnostic providers, laboratories and drug developers, supporting overall U.S. Non-alcoholic Steatohepatitis Biomarkers Market Growth.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Growth Drivers

According to the American Association for the Study of Liver Diseases (AASLD), blood-based biomarkers and imaging-based assessments are important for evaluating hepatic fibrosis and steatosis. FIB-4 and ELF scores support clinical risk stratification and reduce reliance on invasive procedures in appropriate patients, which sustains demand for commercially available biomarker technologies.

The U.S. FDA approved resmetirom on March 14, 2024, for adults with noncirrhotic NASH and moderate-to-advanced fibrosis, and approved semaglutide for adults with MASH in August 2025. These approvals increase the need to identify eligible patients and assess disease severity through diagnostic and biomarker technologies.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Opportunities

GENFIT announced on July 2, 2026, that Medicare coverage had been secured for Labcorp’s NASHnext test, with reimbursement of approximately USD 252 per eligible test effective August 10, 2026. Reimbursement creates room for broader commercialization of specialized blood-based MASH biomarker technologies across U.S. laboratories and clinical settings.

AASLD identifies blood-based and imaging-based assessments as important tools for evaluating hepatic fibrosis. Continued development of improved fibrosis biomarkers, multi-marker panels and treatment-response technologies creates opportunities for diagnostic developers, biotechnology companies and pharmaceutical research partners working on MASH programs.

U.S. Non-alcoholic Steatohepatitis Biomarkers Industry Challenges

According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), blood tests and imaging help assess liver disease, but liver biopsy remains the test that can establish a definitive diagnosis of NASH and determine severity. Additional clinical validation can limit how quickly biomarkers replace established procedures.

According to the FDA, laboratory-developed tests and in-vitro diagnostic products operate under applicable regulatory requirements. Manufacturers must establish analytical and clinical performance, and laboratories must meet validation and quality requirements. Differences in reimbursement coverage and access to specialized testing can also slow commercialization and clinical adoption.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Trends

GENFIT’s NIS4 technology combines multiple biomarkers to identify patients with at-risk MASH. Labcorp commercializes NASHnext using this technology, measuring HbA1c, alpha-2-macroglobulin, miR34a and YKL-40 to produce a diagnostic score. This illustrates the growing development of multi-biomarker blood-based testing solutions.

According to AASLD, non-invasive liver disease assessments include blood-based tests, fibrosis scores and imaging-based methods. These approaches are increasingly incorporated into clinical pathways for evaluating metabolic liver disease and identifying patients who may need further assessment, which defines U.S. Non-alcoholic Steatohepatitis Biomarkers Market Trends.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Segment Analysis

The market is segmented by type and end-use, reflecting the biological markers measured and the organizations that use them. Estimated 2026 shares are based on the supplied figures.

By Type

• Serum Biomarkers
• Hepatic Fibrosis Biomarkers
• Apoptosis Biomarkers
• Oxidative Stress Biomarkers
• Others

Serum biomarkers lead the type category with an estimated 41% share in 2026, supported by the convenience of blood-based sampling and the availability of commercial tests such as NASHnext from Labcorp. Hepatic fibrosis biomarkers follow, driven by the need to identify moderate-to-advanced fibrosis for treatment eligibility. Apoptosis and oxidative stress biomarkers are used mainly in research and drug development settings, while other markers address niche applications. Together, these segments reflect clinical demand for non-invasive assessment and pharmaceutical demand for validated trial endpoints.

By End-use

• Pharma & CRO Industry
• Hospitals
• Diagnostic Labs
• Academic Research Institutes

Pharma and CRO industry leads the end-use category with an estimated 42% share in 2026, driven by clinical trial activity, patient stratification and treatment-response assessment by companies such as AstraZeneca, Pfizer and Bristol-Myers Squibb. Hospitals follow, using biomarkers in risk assessment and patient management. Diagnostic labs, including Quest Diagnostics and Labcorp, provide testing capacity and commercial assays. Academic research institutes contribute through biomarker discovery and validation studies, supporting the broader U.S. Non-alcoholic Steatohepatitis Biomarkers Market Share distribution.

Regional Analysis

The U.S. Non-alcoholic Steatohepatitis Biomarkers Market is assessed across West, Southwest, North and Midwest. Only the North share was supplied; other shares are not disclosed and were not estimated.

North is the leading region with an estimated 32% share in 2026. Its concentration of pharmaceutical companies, academic medical centers and clinical research organizations supports biomarker validation, trial recruitment and specialized laboratory testing for liver disease.

West, Southwest and Midwest contribute through varied healthcare infrastructure, laboratory networks and research capacity. Regional differences in reimbursement coverage, access to specialized testing and clinical adoption of non-invasive liver assessment influence how quickly biomarker technologies move from research settings into routine care.

Market Share & Competitive Landscape

The market includes diagnostic developers, clinical laboratories, medical technology companies and pharmaceutical developers. The table summarizes supplied companies by general capability. It does not represent numerical market share, and U.S. NASH-specific activity should be validated for each company.

Key Companies in the U.S. Non-alcoholic Steatohepatitis Biomarkers Market

GENFIT: GENFIT is a biopharmaceutical company headquartered in Lille, France, focused on liver disease. Its NIS4 technology identifies patients with at-risk MASH using a multi-biomarker score. On July 2, 2026, GENFIT announced Medicare coverage for Labcorp’s NASHnext test, strengthening its U.S. commercial relevance.

Laboratory Corporation of America Holdings (Labcorp): Labcorp is a global clinical laboratory company headquartered in Burlington, North Carolina. It commercializes NASHnext, which uses GENFIT’s NIS4 technology and measures HbA1c, alpha-2-macroglobulin, miR34a and YKL-40. Medicare reimbursement of about USD 252 per eligible test took effect August 10, 2026, supporting its competitive position.

Recent Developments

Market Future Outlook

The U.S. Non-alcoholic Steatohepatitis Biomarkers Market Forecast indicates expansion from USD 0.53 billion in 2026 to USD 2.12 billion by 2034 at an 18.90% CAGR. Growth is expected to depend on treatment approvals, patient identification needs, reimbursement coverage and clinical acceptance of non-invasive blood-based diagnostic approaches.

Investment will likely focus on multi-biomarker panels, fibrosis assessment and treatment-response monitoring. Risks include the continued role of liver biopsy, validation requirements, regulatory obligations and uneven reimbursement. The projected values remain forecast assumptions, and actual outcomes depend on clinical adoption, regulatory decisions and commercial execution.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Report Coverage

This U.S. Non-alcoholic Steatohepatitis Biomarkers Market Report summarizes the supplied valuation, forecast, segmentation, regional framework and competitive ecosystem.

Why Choose This U.S. Non-alcoholic Steatohepatitis Biomarkers Market Report?

• Covers biomarker categories across serum, fibrosis, apoptosis and oxidative stress applications.
• Presents the supplied 2026 valuation, 2034 forecast and 18.90% CAGR clearly.
• Segmentation across five biomarker types and four end-use categories.
• Regional framework covering West, Southwest, North and Midwest.
• Competitive profiling of diagnostic, laboratory and pharmaceutical participants.
• Trend and policy context on FDA approvals, non-invasive testing and reimbursement.
• Forecast insights to support research planning, diagnostic development and market-entry evaluation.